Lexicon Pharmaceuticals (LXRX) Jumped To A New High On Phase 3 Study Results

Lexicon Pharmaceuticals Inc. (LXRX) announced Friday morning that its Phase 3 clinical trial of sotagliflozin met its primary endpoint in patients with type 1 diabetes.

from RTT - Before the Bell http://ift.tt/2cQcCpi
via IFTTT